Literature DB >> 10638671

Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury.

Z Yang1, B Zingarelli, C Szabó.   

Abstract

The nuclear enzyme poly (ADP ribose) synthetase (PARS) has been shown to play an important role in the pathogenesis of various forms of ischemia or reperfusion injury and circulatory shock. Recent studies demonstrated that inhibition or genetic inactivation of PARS is beneficial in the early phase of myocardial reperfusion injury. The aim of the present study was to investigate whether inactivation of PARS influences the delayed myocardial necrosis and the production of the proinflammatory cytokine tumor necrosis factor alpha (TNFalpha), the anti-inflammatory cytokine interleukin-10 (IL-10), and the free radical nitric oxide in the late stage of myocardial reperfusion injury. The results demonstrate that genetic disruption of PARS provides marked protection against the delayed myocardial ischemia and reperfusion injury. In addition, in the absence of functional PARS, a suppression of TNFalpha, IL-10, and nitric oxide production was found. These findings provide direct evidence that PARS activation participates in the development of delayed cell injury and delayed mediator production in myocardial reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10638671     DOI: 10.1097/00024382-200013010-00011

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  26 in total

1.  Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes.

Authors:  Emese Tóth-Zsámboki; Eszter Horváth; Katarina Vargova; Eszter Pankotai; Kanneganti Murthy; Zsuzsanna Zsengellér; Tamás Bárány; Tamás Pék; Katalin Fekete; Róbert Gábor Kiss; István Préda; Zsombor Lacza; Domokos Gerö; Csaba Szabó
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

2.  The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.

Authors:  Akbar Ahmad; Gabor Olah; David N Herndon; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-05       Impact factor: 8.739

Review 3.  Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease.

Authors:  Dominic P Del Re; Dulguun Amgalan; Andreas Linkermann; Qinghang Liu; Richard N Kitsis
Journal:  Physiol Rev       Date:  2019-10-01       Impact factor: 37.312

4.  Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats.

Authors:  Sevil Korkmaz-Icöz; Bartosz Szczesny; Michela Marcatti; Shiliang Li; Mihály Ruppert; Felix Lasitschka; Sivakkanan Loganathan; Csaba Szabó; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-10-02       Impact factor: 8.739

5.  Modulation of poly(ADP-ribose) polymerase-1 (PARP-1)-mediated oxidative cell injury by ring finger protein 146 (RNF146) in cardiac myocytes.

Authors:  Domokos Gerö; Petra Szoleczky; Athanasia Chatzianastasiou; Andreas Papapetropoulos; Csaba Szabo
Journal:  Mol Med       Date:  2014-07-31       Impact factor: 6.354

Review 6.  Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.

Authors:  Inês Falcão-Pires; Adelino F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

Review 7.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

8.  Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury.

Authors:  Basilia Zingarelli; Paul W Hake; Michael O'Connor; Alvin Denenberg; Sue Kong; Bruce J Aronow
Journal:  Mol Med       Date:  2003 May-Aug       Impact factor: 6.354

Review 9.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007

Review 10.  Diabetic cardiomyopathy.

Authors:  Omar Asghar; Ahmed Al-Sunni; Kaivan Khavandi; Ali Khavandi; Sarah Withers; Adam Greenstein; Anthony M Heagerty; Rayaz A Malik
Journal:  Clin Sci (Lond)       Date:  2009-05       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.